Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of Irritable Bowel Syndrome (IBS)~* Experience pain with relief with defecation~* 50/100 or greater of pain or discomfort scores during the two-week baseline period~* At least three pain attacks in a month, with at least three episodes of pain intensity equal to or exceeding 50/100~* U.S. resident~* English-speaking (able to provide consent and complete questionnaires)~* Able to participate in all aspects of the study~Exclusion Criteria:~* Known alternative/concurrent gastrointestinal diagnosis (e.g. Crohn's disease, ulcerative colitis, microscopic colitis, active celiac sprue, chronic pancreatitis or pancreatic insufficiency, scleroderma, chronic intestinal pseudo-obstruction, bacterial overgrowth, recent (\<6 months) intestinal bacterial/protozoal/ parasitic infections, HIV, active pelvic floor dysfunction, paraplegia or quadriplegia);~* Current symptoms of severe depression, as measured by Hospital Anxiety and Depression Scale (HADS) score (greater or less than 15);~* Mental retardation or any condition requiring a legal guardian;~* Current or past history of psychotic disorder (schizophrenia, bipolar disorder)~* Recent or current use (within past 30 days) of drugs that interact with Pregabalin:~* Rosiglitazone (Avandia) or Pioglitazone (Actos)~* Narcotic anti-pain medications (e.g. oxycodone, morphine)~* Anti-anxiety medications (e.g. lorazepam, alprazolam, diazepam)~* Unable to withdraw medications at least 72 hours prior to the study, because we will evaluate patient's response to pregabalin therapy for relief of IBS-associated pain and disturbed sleep.~  1. Non-narcotic anti-pain medications (e.g. nonsteroidal antiinflammatory drug (NSAIDs), ultram, neurontin, etc.)~ 2. Mexiletine, steroids, dextromethorphan.~ 3. Insomnia medications (e.g. benzodiazepines, zolpidem, diphenhydramine, melatonin, etc.)~* Planned surgery (especially transplant) or anesthesia exposure during trial~* Are pregnant, lactating, likely to become pregnant during medication phase and not willing to use a reliable form of contraception (barrier contraceptives, diaphragm, injections, intrauterine device, surgical sterilization, or abstinence)~* Recent or current use (within 30 days) of Pregabalin~* Known allergy to Pregabalin~* Significant acute or chronic progressive neurologic, hepatic, renal, cardiovascular, respiratory or metabolic disease~* Recent history of alcohol or substance dependence use or abuse~* Another household member or relative participating in the study~* Professional drivers or operators of heavy machinery~* Major cardiovascular events in the last 6 months~* Use of IBS-specific drugs such as tegaserod (Zelnorm) and Lotronex (Alosetron) (within 30 days)~* Participation in another clinical trial (within 30 days)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will receive the following dosage:~75 mg (one tablet) twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to this arm will receive placebo matching the study drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).